News | August 26, 2021
Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
It is the first branded generic alternative to Fostair 100/6 pMDI
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
